Trial Profile

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Molnupiravir (Primary)
Indications Chikungunya virus infections; COVID 2019 infections; Eastern equine encephalomyelitis; Ebola virus infections; Influenza virus infections; Middle East respiratory syndrome coronavirus; Respiratory syncytial virus infections; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis
Focus Pharmacokinetics
Sponsors Merck Sharp & Dohme

Most Recent Events

19 Feb 2023 Status changed from active, no longer recruiting to completed.
02 Feb 2023 Planned End Date changed from 18 Apr 2023 to 15 Feb 2023.
02 Feb 2023 Planned primary completion date changed from 7 Apr 2023 to 10 Feb 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com